These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

254 related articles for article (PubMed ID: 30483834)

  • 61. Prognostic significance of tumor-infiltrating immune cells and PD-L1 expression in esophageal squamous cell carcinoma.
    Jiang Y; Lo AWI; Wong A; Chen W; Wang Y; Lin L; Xu J
    Oncotarget; 2017 May; 8(18):30175-30189. PubMed ID: 28404915
    [TBL] [Abstract][Full Text] [Related]  

  • 62. Clinical prognosticators and targets in the immune microenvironment of intrahepatic cholangiocarcinoma.
    Lozzi I; Arnold A; Barone M; Johnson JC; Sinn BV; Eschrich J; Gebert P; Wang R; Hu M; Feldbrügge L; Schirmeier A; Reutzel-Selke A; Malinka T; Krenzien F; Schöning W; Modest DP; Pratschke J; Sauer IM; Felsenstein M
    Oncoimmunology; 2024; 13(1):2406052. PubMed ID: 39359389
    [TBL] [Abstract][Full Text] [Related]  

  • 63. Association of HIV Status With Local Immune Response to Anal Squamous Cell Carcinoma: Implications for Immunotherapy.
    Yanik EL; Kaunitz GJ; Cottrell TR; Succaria F; McMiller TL; Ascierto ML; Esandrio J; Xu H; Ogurtsova A; Cornish T; Lipson EJ; Topalian SL; Engels EA; Taube JM
    JAMA Oncol; 2017 Jul; 3(7):974-978. PubMed ID: 28334399
    [TBL] [Abstract][Full Text] [Related]  

  • 64. Clinicopathological correlation of PD-L1 expression in primary and metastatic breast cancer and infiltrating immune cells.
    Tawfik O; Kimler BF; Karnik T; Shehata P
    Hum Pathol; 2018 Oct; 80():170-178. PubMed ID: 29936058
    [TBL] [Abstract][Full Text] [Related]  

  • 65. Guanylate binding protein 5 is an immune-related biomarker of oral squamous cell carcinoma: A retrospective prognostic study with bioinformatic analysis.
    Hasegawa M; Amano Y; Kihara A; Matsubara D; Fukushima N; Takahashi H; Chikamatsu K; Nishino H; Mori Y; Yoshida N; Niki T
    Cancer Med; 2024 Jul; 13(13):e7431. PubMed ID: 38978333
    [TBL] [Abstract][Full Text] [Related]  

  • 66. Multispectral quantitative immunohistochemical analysis of tumor-infiltrating lymphocytes in relation to programmed death-ligand 1 expression in triple-negative breast cancer.
    Sugie T; Sato E; Miyashita M; Yamaguchi R; Sakatani T; Kozuka Y; Moritani S; Suzuki E; Kakimi K; Mikami Y; Moriya T
    Breast Cancer; 2020 Jul; 27(4):519-526. PubMed ID: 32447649
    [TBL] [Abstract][Full Text] [Related]  

  • 67. Tumor-Infiltrating Immune Cells and PD-L1 as Prognostic Biomarkers in Primary Esophageal Small Cell Carcinoma.
    Wu X; Ke X; Ni Y; Kuang L; Zhang F; Lin Y; Lin W; Xiong X; Huang H; Lin X; Zhang H
    J Immunol Res; 2020; 2020():8884683. PubMed ID: 33457428
    [TBL] [Abstract][Full Text] [Related]  

  • 68. Characterization of Immune Infiltrate Along the Leading Edge of Differentiated Thyroid Cancer.
    Kotwal A; Vance K; Hajric K; Yuil-Valdes A; Swanson B; Martinez Duarte E; Shats O; Hollingsworth M; Band H; Goldner W
    Thyroid; 2024 Aug; 34(8):999-1006. PubMed ID: 38916182
    [No Abstract]   [Full Text] [Related]  

  • 69. Clinicopathologic implications of immune classification by PD-L1 expression and CD8-positive tumor-infiltrating lymphocytes in stage II and III gastric cancer patients.
    Koh J; Ock CY; Kim JW; Nam SK; Kwak Y; Yun S; Ahn SH; Park DJ; Kim HH; Kim WH; Lee HS
    Oncotarget; 2017 Apr; 8(16):26356-26367. PubMed ID: 28412752
    [TBL] [Abstract][Full Text] [Related]  

  • 70. PD-L1 expression in colorectal cancer is associated with microsatellite instability, BRAF mutation, medullary morphology and cytotoxic tumor-infiltrating lymphocytes.
    Rosenbaum MW; Bledsoe JR; Morales-Oyarvide V; Huynh TG; Mino-Kenudson M
    Mod Pathol; 2016 Sep; 29(9):1104-12. PubMed ID: 27198569
    [TBL] [Abstract][Full Text] [Related]  

  • 71. Combined Positive Score for Programmed Death Ligand-1 Expression and Inflammatory Microenvironment in Gastrointestinal Stromal Tumors.
    Herlea V; Roșulescu A; Calotă VC; Croitoru V; Stoica Mustafa E; Vasilescu C; Alexandrescu S; Dumitrașcu T; Popescu I; Dima SO; Sajin M
    Medicina (Kaunas); 2022 Jan; 58(2):. PubMed ID: 35208498
    [No Abstract]   [Full Text] [Related]  

  • 72. Expression of PD-L1, PD-L2, and IDO1 on tumor cells and density of CD8-positive tumor-infiltrating lymphocytes in early-stage lung adenocarcinoma according to histological subtype.
    Takada K; Toyokawa G; Kinoshita F; Jogo T; Kohashi K; Wakasu S; Ono Y; Tanaka K; Oba T; Osoegawa A; Tagawa T; Azuma K; Okamoto I; Shimokawa M; Oda Y; Mori M
    J Cancer Res Clin Oncol; 2020 Oct; 146(10):2639-2650. PubMed ID: 32405745
    [TBL] [Abstract][Full Text] [Related]  

  • 73. PD-L1 and PD-L2 expression in the tumor microenvironment including peritumoral tissue in primary central nervous system lymphoma.
    Furuse M; Kuwabara H; Ikeda N; Hattori Y; Ichikawa T; Kagawa N; Kikuta K; Tamai S; Nakada M; Wakabayashi T; Wanibuchi M; Kuroiwa T; Hirose Y; Miyatake SI
    BMC Cancer; 2020 Apr; 20(1):277. PubMed ID: 32248797
    [TBL] [Abstract][Full Text] [Related]  

  • 74. Cancer cell-specific PD-L1 expression is a predictor of poor outcome in patients with locally advanced oral cavity squamous cell carcinoma.
    Wang M; Qin L; Thia K; Nguyen T; MacDonald S; Belobrov S; Kranz S; Goode D; Trapani JA; Wiesenfeld D; Neeson PJ
    J Immunother Cancer; 2024 Oct; 12(10):. PubMed ID: 39357980
    [TBL] [Abstract][Full Text] [Related]  

  • 75. Prognostic Significance of Programmed Cell Death Ligand 1 (PD-L1), CD8+ Tumor-Infiltrating Lymphocytes and p53 in Non-Small Cell Lung Cancer: An Immunohistochemical Study.
    Rashed HE; Abdelrahman AE; Abdelgawad M; Balata S; Shabrawy ME
    Turk Patoloji Derg; 2017; 1(1):211-222. PubMed ID: 28832075
    [TBL] [Abstract][Full Text] [Related]  

  • 76. Prognostic value of tumor-infiltrating lymphocytes and PD-L1 expression in esophageal squamous cell carcinoma.
    Hu J; Toyozumi T; Murakami K; Endo S; Matsumoto Y; Otsuka R; Shiraishi T; Iida S; Morishita H; Makiyama T; Nishioka Y; Uesato M; Hayano K; Nakano A; Matsubara H
    Cancer Med; 2024 Sep; 13(17):e70179. PubMed ID: 39264227
    [TBL] [Abstract][Full Text] [Related]  

  • 77. PD-L1 expression and infiltration by CD4
    Lee HJ; Shin DH; Lee YJ; Lee SJ; Hwang CS; Kim A; Park WY; Lee JH; Choi KU; Kim JY; Lee CH; Sol MY; Park SW
    Histopathology; 2020 Apr; 76(5):714-721. PubMed ID: 31841221
    [TBL] [Abstract][Full Text] [Related]  

  • 78. Immune Marker Profiling and Programmed Death Ligand 1 Expression Across NSCLC Mutations.
    Toki MI; Mani N; Smithy JW; Liu Y; Altan M; Wasserman B; Tuktamyshov R; Schalper K; Syrigos KN; Rimm DL
    J Thorac Oncol; 2018 Dec; 13(12):1884-1896. PubMed ID: 30267840
    [TBL] [Abstract][Full Text] [Related]  

  • 79. Association of cancer progression with elevated expression of programmed cell death protein 1 ligand 1 by upper tract urothelial carcinoma and increased tumor-infiltrating lymphocyte density.
    Nukui A; Kamai T; Arai K; Kijima T; Kobayashi M; Narimatsu T; Kambara T; Yuki H; Betsunoh H; Abe H; Fukabori Y; Yashi M; Yoshida KI
    Cancer Immunol Immunother; 2020 May; 69(5):689-702. PubMed ID: 32030476
    [TBL] [Abstract][Full Text] [Related]  

  • 80. HHLA2 in intrahepatic cholangiocarcinoma: an immune checkpoint with prognostic significance and wider expression compared with PD-L1.
    Jing CY; Fu YP; Yi Y; Zhang MX; Zheng SS; Huang JL; Gan W; Xu X; Lin JJ; Zhang J; Qiu SJ; Zhang BH
    J Immunother Cancer; 2019 Mar; 7(1):77. PubMed ID: 30885276
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 13.